NEW YORK (360Dx) – Vermillion said today it has entered into a contracted agreement with Blue Cross Blue Shield of Illinois for its OVA1 ovarian cancer test.
BCBS of Illinois is the largest PPO network in the state, covering roughly 7.9 million people.
"We are making considerable strides in expanding access to OVA1, said Fred Ferrara, Vermillion's chief operating officer. "Our increase in payer contracts will allow the majority of the population in the markets we serve to access OVA1."
Vermillion now has more than 120 million US lives covered for OVA1, a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.